TGN 1412, with the CAS number 906068-56-2, is a monoclonal antibody that was initially developed for therapeutic use in autoimmune diseases and certain types of cancer. It is designed to target the CD28 receptor on T cells, which plays a crucial role in T cell activation and proliferation. TGN 1412 is notable for its ability to stimulate a strong immune response, which can lead to cytokine release syndrome, a potentially severe adverse effect. This characteristic was highlighted during a clinical trial in 2006, where participants experienced severe inflammatory reactions. The substance is classified as an immunomodulator and is part of a broader category of biologics. Its structure consists of humanized IgG, which enhances its stability and reduces immunogenicity compared to fully murine antibodies. While TGN 1412 has shown promise in preclinical studies, its safety profile has raised significant concerns, leading to a reevaluation of its therapeutic potential and the need for stringent safety assessments in future trials.

TGN 1412

906068-56-2: TGN 1412, with the CAS number 906068-56-2, is a monoclonal antibody that was initially developed for therapeutic use in autoimmune diseases and certain types of cancer. It is designed to target the CD28 receptor on T cells, which plays a crucial role in T cell activation and proliferation. TGN 1412 is notable for its ability to stimulate a strong immune response, which can lead to cytokine release syndrome, a potentially severe adverse effect. This characteristic was highlighted during a clinical trial in 2006, where participants experienced severe inflammatory reactions. The substance is classified as an immunomodulator and is part of a broader category of biologics. Its structure consists of humanized IgG, which enhances its stability and reduces immunogenicity compared to fully murine antibodies. While TGN 1412 has shown promise in preclinical studies, its safety profile has raised significant concerns, leading to a reevaluation of its therapeutic potential and the need for stringent safety assessments in future trials.

<p>Theralizumab (TGN1412) is a monoclonal antibody for treating leukemia and arthritis by stimulating T cells.</p>

CAS 906068-56-2

TGN 1412

Theralizumab

Ref: TM-T77093

Theralizumab

Ref: 54-BUP20205